Why you should back a biotech

Financial journalist and commentator on 3AW and Sky Business
Print This Post A A A

The 100-plus life sciences companies listed on the Australian Securities Exchange (ASX) do an amazing variety of things. Australian medical research is world-class and it can give rise to globally successful drugs and diagnostics.

But it is a lonely road trying to struggle along alone in a southern hemisphere market: Australian biotechs need to catch the eye of northern hemisphere backers to make a real mark.

It’s also important to note that they can be quite speculative and don’t suit the risk profiles of all investors.

Also from this edition